Insight regarding updates to the management of patients with colorectal cancer who are microsatellite instability-high (MSI-H)/mismatch repair deficient, harbor a 

Data from the following clinical trials is discussed:

Pembrolizumab vs chemotherapy for MSI-H/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 study. (Andre T, et al. ASCO 2020. LBA4)

Encorafenib plus cetuximab +/- binimetinib for 

 V600E metastatic colorectal cancer: BEACON CRC updated survival results (Kopetz S, et al. ASCO 2020. Abstract 4001)

A phase 2, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with 

-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01. (Siena S, et al. ASCO 2020. Abstract 4000)

Colorectal Cancer Updates

Important considerations regarding the sequencing of novel therapies for gastric cancer based on updates presented at the ASCO 2020 Virtual Meeting.

Pembrolizumab vs paclitaxel for previously treated pts with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase 3 KEYNOTE-061 trial. (Fuchs CS, et al. ASCO 2020. Abstract 4503)

KEYNOTE-158: FDA approval of pembrolizumab based on tumor mutational burden-high (TMB-high) (FDA.gov; Marabelle A, et al. 

WES, cut-off 175 mutations/exome (Fuchs CS, et al. ASCO 2020. Abstract 4512)

FoundationOne CDx (F1CDx); Foundation Medicine cut-off 10 mut/MB (Shitara K, et al. ASCO 2020. Abstract 4537)

T-DXd; DS-8201 in pts with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01). (Shitara K, et al. ASCO 2020. Abstract 4513)

Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010. (Safran H, et al. ASCO 2020. Abstract 4500)

Perioperative trastuzumab and pertuzumab in combination with FLOT for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase 2 trial of the AIO. (Dieter Hofheinz R, et al. ASCO 2020. Abstract 4502)

FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for pts with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel: Results from the phase 2 RAMIRIS Study of the AIO.

Lorenzen S, et al. ASCO 2020. Abstract 4514

Gastric Cancer Updates

Experts who treat gastrointestinal malignancies discuss the appropriateness for lenvatinib plus pembrolizumab in unresectable hepatocellular carcinoma following the release of phase 1b data presented at the ASCO 2020 Virtual Meeting.

Data from an early-phase study of lenvatinib plus pembrolizumab in unresectable hepatocellular carcinoma is discussed. (ClinicalTrials.gov Identifier: NCT03006926)

Liver Cancer Updates

GI oncologists discuss the rationale behind the SWOG S1505 study in pancreatic cancer and provide recommendations for managing patients with resectable disease based on the most current data.

SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mFOLFIRINOX vs gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA

ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase 2 trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in pts with borderline resectable pancreatic cancer

Ghaneh P, et al. ASCO 2020. Abstract 4505

“GI Talk”: A Review of Data from the ASCO 2020 Virtual Meeting | The Talk

EP 1: Colorectal Cancer Updates

EP 2: Gastric Cancer Updates

EP 3: Liver Cancer Updates

EP 4: Pancreatic Cancer Updates